Intraocular Distribution and Kinetics of Intravitreally Injected Antibodies and Nanoparticles in Rabbit Eyes
Open accessAbstract
Purpose: To investigate the intraocular distribution and kinetics of antibodies and nanoparticles in the experimental model. Methods: Antibodies (whole IgG 149kDa, antigen-binding fragments 48.39 kDa) and four kinds of nondegradable nanoparticles (25, 50, 200, and 250 nm) were intravitreally injected in the right eye of New Zealand white rabbits. The average optical density and concentration were used to measure intraocular distribution and kinetics. Results: After intravitreal injection, antibodies were distributed throughout the vitreous humor and eliminated gradually into anterior and posterior routes. Fluorescence intensity decreased 1 day after injection and was not detected 25 days after injection. The nondegradable nanoparticles migrated posteriorly to the retina 7 days after injection onward and anteriorly to the aqueous humor from 1 hour to 1 day after injection. The fluorescence intensity of the nanoparticles was relatively stable in the vitreous humor, compared to antibodies. Nanoparticles accumulated on the internal limiting membrane of the retina with no penetration into deeper retinal tissue, whereas the smaller size 25 nm nanoparticles passed across the ciliary body and moved into choroid, retina, and suprachoroidal space. A gradual decrease of nanoparticles by their sizes in the vitreous after 30 days after injection was described as the percentage ratio: 61.1% (25 nm), 69.1% (50 nm), 78.6% (200nm), and 85.3% (250 nm). Conclusions: Our study revealed the in vivo intraocular distribution and kinetics of antibodies and nanoparticles with diverse sizes and the result might help to develop newer intraocular drugs and drug delivery systems to treat retinal diseases. Translational Relevance: These experimental results can be valuable data for human research.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Intraocular antibodies appear capable of limited transport between vitreous fluid and the retina.
“Furthermore, intraocular antibodies appear capable of limited transport between vitreous fluid and the retina32.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886 · see citing works
Ranibizumab for Macular Edema following Central Retinal Vein Occlusion
Brown, D. M., Campochiaro, P. A., Singh, R. P., Li, Z., Gray, S., Saroj, N., Rundle, A. C., Rubio, R. G., & Murahashi, W. Y. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.022 · Cited by 1,158 · see citing works
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849 · see citing works
Campochiaro, P. A., Brown, D. M., Awh, C. C., Lee, S.-H., Gray, S., Saroj, N., Murahashi, W. Y., & Rubio, R. G. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.02.038 · Cited by 712 · see citing works
Pharmacokinetics of Intravitreal Bevacizumab (Avastin)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.017 · Cited by 683 · see citing works
(2020) · Clinical ophthalmology · doi:10.2147/opth · Cited by 590 · see citing works
Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., Ezzat, M. K., & Singh, R. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.012 · Cited by 543 · see citing works
Brown, D. M., Campochiaro, P. A., Bhisitkul, R. B., Ho, A. C., Gray, S., Saroj, N., Adamis, A. P., Rubio, R. G., & Murahashi, W. Y. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.02.022 · Cited by 465 · see citing works
Anti-vascular endothelial growth factor therapy for ocular neovascular disease
Andreoli, C. M., & Miller, J. W. (2007) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3282f0ca54 · Cited by 274 · see citing works
Nomoto, H., Shiraga, F., Kuno, N., Kimura, E., Fujii, S., Shinomiya, K., Nugent, A. K., Hirooka, K., & Baba, T. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-3148 · Cited by 269 · see citing works
Koo, H., Moon, H., Han, H., Na, J. H., Huh, M. S., Park, J. H., Woo, S. J., Park, K. H., Kwon, I. C., Kim, K., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.01.030 · Cited by 215 · see citing works
Self-citationVitreous: A Barrier to Nonviral Ocular Gene Therapy
Peeters, L., Sanders, N. N., Braeckmans, K., Boussery, K., Van de Voorde, J., De Smedt, S. C., & Demeester, J. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0165 · Cited by 189 · cited 1× · see citing works
“34 These polyanionic glycosaminoglycans such as hyaluronic acid and heparan sulfate are suggested as the key molecule for the charge-selective trapping ability of the vitreous humor, which is critical in intraocular diffusion.”
Gaudreault, J., Fei, D., Beyer, J. C., Ryan, A. M., Rangell, L. K., Shiu, V., & Damico, L. A. (2007) · Retina · doi:10.1097/iae.0b013e318134eecd · Cited by 182 · see citing works
Martens, T., Remaut, K., Deschout, H. G., Engbersen, J. F. J., Hennink, W. E., van Steenbergen, M. J., Demeester, J., Smedt, S. C. D., & Braeckmans, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.030 · Cited by 157 · see citing works
Effect of Particle Size of Polymeric Nanospheres on Intravitreal Kinetics
Sakurai, E., Ozeki, H., Kunou, N., & Ogura, Y. (2000) · Ophthalmic Research · doi:10.1159/000055638 · Cited by 156 · see citing works
Niwa, Y., Kakinoki, M., Sawada, T., Wang, X., & Ohji, M. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-17279 · Cited by 142 · see citing works
Gold nanoparticles in ophthalmology
Masse, F., Ouellette, M., Lamoureux, G., & Boisselier, É. (2018) · Medicinal Research Reviews · doi:10.1002/med.21509 · Cited by 130 · see citing works
Amrite, A. C., Edelhauser, H. F., Singh, S. R., & Kompella, U. B. (2008) · PubMed Central · Cited by 125 · see citing works
Intravital imaging of intestinal lacteals unveils lipid drainage through contractility
Choe, K., Jang, J. Y., Park, I., Kim, Y.-S., Ahn, S., Park, D.-Y., Hong, Y., Alitalo, K. K., Koh, G. Y., & Kim, P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76509 · Cited by 116 · see citing works
Self-citationDiffusion Regulation in the Vitreous Humor
Käsdorf, B. T., Arends, F., & Lieleg, O. (2015) · Biophysical Journal · doi:10.1016/j.bpj.2015.10.002 · Cited by 113 · see citing works
Intraocular Pharmacokinetics of Ranibizumab in Vitrectomized Versus Nonvitrectomized Eyes
Ahn, S. J., Ahn, J., Park, S. Y., Kim, H., Hwang, D. D.-J., Park, J. H., Park, J. Y., Chung, J., Park, K. H., & Woo, S. J. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13054 · Cited by 110 · see citing works
Self-citationPark, J., Bungay, P. M., Lutz, R. J., Augsburger, J. J., Millard, R. W., Roy, A. S., & Banerjee, R. K. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.03.010 · Cited by 107 · see citing works
Hyaluronic Acid Coated Albumin Nanoparticles for Targeted Peptide Delivery to the Retina
Huang, D., Chen, Y.-S., & Rupenthal, I. D. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01029 · Cited by 104 · see citing works
Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model
Park, S. J., Choi, Y., Na, Y. M., Hong, H. K., Park, J. Y., Park, K. H., Chung, J., & Woo, S. J. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19204 · Cited by 94 · see citing works
Self-citationMeasuring The Intravitreal Mobility of Nanomedicines with Single-Particle Tracking Microscopy
Martens, T., Vercauteren, D., Forier, K., Deschout, H. G., Remaut, K., Paesen, R., Ameloot, M. M., Engbersen, J. F. J., Demeester, J., Smedt, S. C. D., et al. (2013) · Nanomedicine · doi:10.2217/nnm.12.202 · Cited by 94 · see citing works
Gan, L., Wang, J., Zhao, Y., Chen, D., Zhu, C., Liu, J., & Gan, Y. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.035 · Cited by 93 · see citing works
Inokuchi, Y., Hironaka, K., Fujisawa, T., Tozuka, Y., Tsuruma, K., Shimazawa, M., Takeuchi, H., & Hara, H. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4697 · Cited by 90 · see citing works
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
Sinapis, Sinapis, C., Σινάπης, Δ., Routsias, J. G., Pantopoulou, A., Baltatzis, S., Patsouris, E., & Perrea, D. N. (2011) · Clinical ophthalmology · doi:10.2147/opth.s19555 · Cited by 87 · see citing works
Pharmacokinetics of Intravitreally Injected Bevacizumab in Vitrectomized Eyes
Ahn, J., Kim, H., Woo, S. J., Park, J. H., Park, S. Y., Hwang, D. D.-J., & Park, K. H. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2013.0009 · Cited by 85 · see citing works
Self-citationLaude, A., Tan, L. E., WILSON, C. G., Lascaratos, G., Elashri, M., Aslam, T. M., Patton, N., & Dhillon, B. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.003 · Cited by 84 · see citing works
Hutton-Smith, L. A., Gaffney, E. A., Byrne, H. M., Maini, P. K., Gadkar, K. G., & Mazer, N. A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00164 · Cited by 71 · see citing works
Hwang, Y., Ahn, J., Mun, J., Bae, S., Jeong, Y. U., Винокуров, Н. А., & Kim, P. (2014) · Optics Express · doi:10.1364/oe.22.011465 · Cited by 55 · see citing works
Self-citationPark, S. J., Oh, J., Kim, Y., Park, J.-H., Park, J. Y., Hong, H. K., Park, K. H., Lee, J.-W., Kim, H., Chung, J., et al. (2015) · Eye · doi:10.1038/eye.2014.329 · Cited by 49 · see citing works
Self-citationHuang, X., & Chau, Y. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107711 · Cited by 37 · see citing works
Role of the Fc Region in the Vitreous Half-Life of Anti-VEGF Drugs
Joo, K., Park, S. J., Choi, Y., Lee, J. E., Na, Y. M., Hong, H. K., Park, K. H., Kim, H. M., Chung, J., & Woo, S. J. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-21813 · Cited by 22 · see citing works
Self-citationNishihara, H. (1991) · PubMed · Cited by 20 · see citing works
Kim, H. M., Park, K. H., Chung, J., & Woo, S. J. (2019) · Ophthalmic Research · doi:10.1159/000499529 · Cited by 18 · see citing works
Self-citationNishihara, H. (1989) · PubMed · Cited by 10 · see citing works
Flagged first, then by citations
1 of the 39 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198 · see citing works
Self-citationAlshaikh, R. A., Waeber, C., & Ryan, K. B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114342 · Cited by 108 · see citing works
Nanomaterial-based ophthalmic drug delivery
Xie, G., Lin, S., Wu, F. Q., & Liu, J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115004 · Cited by 79 · see citing works
Silva, M., Peng, T., Zhao, X., Li, S., Farhan, M., & Zheng, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.007 · Cited by 58 · see citing works
Ottonelli, I., Bighinati, A., Adani, E., Loll, F., Caraffi, R., Vandelli, M. A., Boury, F., Tosi, G., Duskey, J. T., Marigo, V., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010025 · Cited by 36 · see citing works
Imaging, quantitation and kinetic modelling of intravitreal nanomaterials
Sadeghi, A., Ruponen, M., Puranen, J., Cao, S., Ridolfo, R., Tavakoli, S., Toropainen, E., Lajunen, T., Ranta, V., van Hest, J. C. M., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121800 · Cited by 29 · see citing works
Investigation of Cas9 Antibodies in the Human Eye
Toral, M. A., Charlesworth, C. T., Ng, B., Chemudupati, T., Homma, S., Nakauchi, H., Bassuk, A. G., Porteus, M. H., & Mahajan, V. B. (2022) · Nature Communications · doi:10.1038/s41467-022-28674-1 · Cited by 28 · see citing works
Intravitreal injectable hydrogel rods with long-acting bevacizumab delivery to the retina
Lee, S., Hong, H. K., Song, J. S., Jeong, S. I., Chung, J., Woo, S. J., & Park, K. D. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.09.025 · Cited by 28 · see citing works
Self-citationUtilizing extracellular vesicles as a drug delivery system in glaucoma and RGC degeneration
Durmaz, E., Dribika, L., Kutnyanszky, M., & Mead, B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.029 · Cited by 20 · see citing works
Naik, K., du Toit, L. C., Ally, N., & Choonara, Y. E. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01566-1 · Cited by 17 · see citing works
Noh, S., Hong, H. K., Kim, D. G., Jeong, H., Lim, S. J., Kim, J., Woo, S. J., & Choi, H. (2024) · ACS Omega · doi:10.1021/acsomega.3c07033 · Cited by 16 · see citing works
Self-citationLuo, J., Tan, G., Thong, K. X., Kafetzis, K. N., Vallabh, N. A., Sheridan, C., Sato, Y., Harashima, H., Tagalakis, A. D., & Yu‐Wai‐Man, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112472 · Cited by 15 · see citing works
Ophthalmic dosage forms for drug delivery to posterior segment
Lee, J., & Rhee, Y.-S. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00554-8 · Cited by 12 · see citing works
Intraocular injectable hydrogels for the delivery of cells and nanoparticles
Moreno, E. I., Alonso, M. J., & Abbadessa, A. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101767 · Cited by 10 · see citing works
Evaluating the safety and efficiency of nanomaterials: A focus on mitochondrial health
Siquan, L., Weilin, C., Chen, X., Meiyan, Z., Weihong, G., & Xiaoli, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117484 · Cited by 9 · see citing works
A journey through the world of vitreous
Ayalon, A., Sahel, J., & Chhablani, J. K. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.06.004 · Cited by 8 · see citing works
Active Transport and Ocular Distribution of Intravitreally Injected Liposomes
Eriksen, A. Z., Melander, F., Eriksen, G. D. M., Kempen, P. J., Kjær, A., Andresen, T. L., & Urquhart, A. J. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.8.20 · Cited by 7 · see citing works
Sjöbom, U., Hellqvist, T., Humayun, J., Nilsson, A., Gyllensten, H., Hellström, A., & Löfqvist, C. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100548 · Cited by 7 · see citing works
Бахрушина, Е. О., Dubova, A. I., Nikonenko, M. S., Grikh, V. V., Shumkova, M. M., Korochkina, T. V., Krasnyuk, I. I., & Krasnyuk, I. I. (2023) · Gels · doi:10.3390/gels9090693 · Cited by 7 · see citing works
Breaking the ocular barrier through nano-lipid carriers to treat intraocular diseases
Giri, S., Badwaik, H. R., & Giri, T. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104867 · Cited by 5 · see citing works
Exosomes in treating Eye Diseases: Targeting strategies
Ge, P., Wang, J., Xie, P., & Hu, Z. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123598 · Cited by 4 · see citing works
Sun, H., Guo, R., Feng, Q., Zhang, X., Li, K., Zheng, N., He, L., & Liu, S. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.10.110 · Cited by 3 · see citing works
Pharmacokinetic considerations and strategies for antibody-based therapeutics
Zhang, J., Chang, R., Zhao, A., Li, X., Sun, Y., Zhang, J., Wang, R., & Jin, T. (2025) · Drug Metabolism Reviews · doi:10.1080/03602532.2025.2595941 · Cited by 2 · see citing works
Guo, R., Zhang, X., Song, Y., Shen, J., Li, K., & Zheng, Y. (2025) · Materials · doi:10.3390/ma18184384 · Cited by 1 · see citing works
Liang, F., Wang, Y., Li, N., Liu, Y., Gao, Y., Song, Y., Zhao, Z., Wang, Y., & Liu, H. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114903 · Cited by 1 · see citing works
Pelaez, D., Gallo, R. A., Dvoriantchikova, G., Moeyersoms, A. H. M., Wang, H., Moulin, C., Torres, Z. A., Lang, S. H., & Ivanov, D. (2022) · Research Square · doi:10.21203/rs.3.rs-1690038/v1
Tomazoni, E., Penha, F. M., & Rodrigues, E. B. (2025) · Springer eBooks · doi:10.1007/978-3-031-29358-0_18-1
A method to quantify ligand-neuron binding in vivo
Kaur, A., Zhang, B., Bao, H., Frankfort, B. J., & Li, W. (2026) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2026.110911
DNA Origami Uptake in Y‐79 Retinoblastoma Cells Driven by Oligolysine Coating
Klose, A., Gounani, Z., Raik, S. V., Koivuniemi, A., Korhonen, S., Reinisalo, M., Lajunen, T., Linko, V., & Laaksonen, T. (2026) · Small Structures · doi:10.1002/sstr.70628
Tomazoni, E., Penha, F. M., & Rodrigues, E. B. (2026) · Springer eBooks · doi:10.1007/978-3-032-23052-2_18
- Authors
- Kim, H. M., Ha, S., Hong, H. K., Hwang, Y., Kim, P., Yang, E., Chung, J. Y., Park, S., Park, Y. J., Park, K. H., Kim, H., & Woo, S. J.
- Affiliations
- Seoul National University (KR)
- Daegu TechnoPark (KR)
- Korea Advanced Institute of Science and Technology (KR)
- Sogang University (KR)
- Corresponding author
- Woo, Se Joon
- ORCID
- Venue
- Translational Vision Science & Technology
- Published
- 2020-05-20
- Volume
- 9
- Issue
- 6
- Pages
- 20
- ISSN
- 2164-2591 (ISSN-L)
- PMC
- PMC7409074
- OpenAlex
- W3027596375
- Cited by
- 30
- References
- 39
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 7 · 2021: 2
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Translational Vision Science & Technology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Seoul National University Bundang Hospital
- National Research Foundation
- Seoul National University
- Ministry of Science and ICT, South Korea
- Samsung
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- intravitreal injection, nanoparticles, immunoglobulins, vitreous humor, retinal drug delivery, nanoparticle size, internal limiting membrane, choroid, aqueous humor, retinal disease, rabbit eye
- MeSH terms
- Animals, Choroid, Kinetics, Rabbits, Vitreous Body, Nanoparticles, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
